Complex generics will boost speciality biz, Teva says

Complex generics will boost speciality biz, Teva says

Complex generics will represent over 50% of Teva’s generic market by 2017, the firm says, but investments in delivery technology will have positive implications across the full business.

During a standing-room only session at yesterday’s JP Morgan Global Healthcare Conference, Teva’s acting CEO Eyal Desheh, and President of R&D, Michael Hayden spoke about the firm’s strategy and its move towards complex generics.

According to the US Food and Drug Administration (FDA), complex generics are off patent versions of drugs that may involve complex APIs such as peptides or natural source products, complex formulation process, a unique route of delivery, or a drug-device combination, and therefore offer a high-barrier to entry.

“We are moving very intensely into the complex generic products, creating more barriers to copying these products, using novel complex technologies,” Hayden said. By 2017 “significantly more than 50% of [Teva’s] generic market will be in complex generic products,” he continued, adding the company was spending “significant amounts from [its] generic R&D budget in the development of complex technology.”

Whilst some technology will be developed in-house, others will be brought in via licensing agreements or acquired, he added, saying this “major commitment” was supported by recent recruitments as Erez Vigodman, who has just been selected as the new CEO.

However, whilst Teva is the world’s largest generics firm by revenue, Hayden told potential investors it is “the only company in the world with a truly integrated generic and branded R&D portfolio,” and recent in-house delivery technology developments - including patches, injectable devices, nasal suspension and long-acting injectables - would equally support the firm’s specialty drug business.

“These particular technologies have been the basis for the development of our NTE [new therapeutic entities] programme, which is seeing 14 new products this year coming out that were essentially an idea a year ago and are coming out a year later.”

Copaxone

On example of complex technology bolstering Teva’s speciality business is with its top multiple sclerosis drug, Copaxone (worth $4bn (€2.9bn) in 2012), coming off patent later this year.

However, the firm has reformulated the drug to a thrice-weekly injection and, according to Hayden, is “completely confident of approval of approval” in the US in the near future.

He continued to add Teva was looking conservatively at up to 45% patient switching before Copaxone expires in June.

M&A

Teva has also undertaken a cost-cutting strategy which it hopes to save $2bn annually by 2017. However, with the savings - plus recent financial settlements with Pfizer and a fully paid $700m tax bill to the Israeli Government - acting CEO Desheh said yesterday Teva was in a position to “more than a small acquisition or in-licensing transaction,” raising a laugh by hinting potential targets were roaming the corridors of the conference.

For the increasingly consolidated generics industry, the major players are all looking to move fast on the same targets, he continued, though stressed whilst there is a rush to acquire, “let’s not confuse sense of urgency with doing dumb deals.”

Consolidation

When asked whether the Big Four players - Teva, Sandoz, Actavis and Mylan, according to this report - were likely to become the Big Three, Desheh admitted it might be a possibility.

“A lot of smaller players mostly outside of US that will be consolidated, they will not survive the competition,” he said. “Economically does it makes sense to reduce the big four competitiors to three? Probably yes. Legally, with anti-trust issues I’m not sure it’s possible but there will be people looking at it over the next few months.”

Related News

Democrats, Republicans spar over impact of US FDA proposed rule for generic manufacturers

Politicians spar over US FDA proposed rule for generic manufacturers

Teva is keen to expand its biosimilars portfolio

Teva: ‘No’ to future JVs with Lonza, yes to biosimilar growth

Teva workers in the granulation department

Teva to close 11 plants in $2bn cost-cutting plan

Mylan has acquired Abbott's EpiPen. (Picture credit: Greg Friese/Flickr)

Mylan buys Abbott’s generics business for $5.3bn

Generics: change in pill shape makes patients 66% more likely to quit

Generics: change in pill shape makes patients 66% more likely to quit

Some drugmakers patent their patient screening tests

The key to market exclusivity? Forget molecules, patent your tests

The stagnation in Europe comes as the US and so-called ‘pharmerging’ markets are expected to account for more than 60% of sales and 80% of the world's growth over the next five years

Message is clear: Europe is in trouble in terms of pharma growth, experts say

Mylan a megamerger with Teva is "clearly in no one's best interest"

Mylan rejects $40bn bid, questions Teva’s credibility

Endo buys Par, Lupin enters Brazil. It's been a busy week for generics

Endo buys Par, Lupin enters Brazil... it's been a busy week in generics

Teva calls in pesticides CEO to exterminate costs

Teva calls in pesticides CEO to exterminate costs

MHRA suspends license of Teva generic over dissolution fears

MHRA suspends license of Teva generic over dissolution fears

Teva to benefit from changing Japanese attitudes

Teva Doubles Production as Japanese Change Attitude to Generics

Teva CEO resigns days after denying departure rumors

Teva CEO resigns days after denying departure rumors

The new Croatian plant will provide exports to the US, EU

Teva subsidiary opens $100m manufacturing facility in Croatia

On the up - People on the Move

Teva names interim CEO; New CFO at AZ - People on the Move

Teva to sell its Californian plant

Teva to Sell Californian Plant as Part of Cost-Cutting Initiative

MicroDose of Fresh Air for Teva with Respiratory Acquisition

MicroDose of Fresh Air for Teva with Respiratory Acquisition

Related Products

See more related products